Most cited papers from Medical Plus

Medical Plus

What are the most cited papers from Medical Plus?

The most cited paper from Medical Plus is "Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial" (Bente Lomholt Langdahl et al., 2017), with 489 citations. Next come "Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study" (293) and "Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2" (239).

Published TypeFieldAccessCitations

Showing 50 of 62 papers. Every paper with more than 4 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial Bente Lomholt Langdahl et al. · The Lancet	26 Jul 2017	489
2	Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study Mark C. Genovese, Patrick Durez, Hanno B. Richards et al. · Annals of the Rheumatic Diseases	24 Jun 2012	293
3	Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 Philip J. Mease, Apinya Lertratanakul, Jaclyn K. Anderson et al. · Annals of the Rheumatic Diseases Open access	3 Dec 2020	239
4	Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3 Karel Pavelka, Alan Kivitz, Eva Dokoupilová et al. · Arthritis Research & Therapy Open access	Dec 2017	234
5	Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study Francisco Javier Blanco, Rüdiger Möricke, Eva Dokoupilová et al. · Arthritis & Rheumatology	19 Feb 2017	187
6	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) on behalf of the FUTURE 3 study group, Peter T. Nash, Philip J. Mease et al. · Arthritis Research & Therapy Open access	15 Mar 2018	170
7	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy Jung‐Yoon Choe, Nenad Prodanović, Jaroslaw Niebrzydowski et al. · Annals of the Rheumatic Diseases Open access	Dec 2015	167
8	Transport Properties of Bulk Thermoelectrics: An International Round-Robin Study, Part II: Thermal Diffusivity, Specific Heat, and Thermal Conductivity Hsin Wang, Wallace D. Porter, H. Böttner et al. · Journal of Electronic Materials	12 Mar 2013	166
9	Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study Atul A. Deodhar, Ricardo Blanco, Eva Dokoupilová et al. · Arthritis & Rheumatology Open access	8 Aug 2020	163
10	Phase III Randomized Study of SB 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis Michael E. Weinblatt, Asta Baranauskaitė, Jaroslaw Niebrzydowski et al. · Arthritis & Rheumatology Open access	26 Sep 2017	133
11	Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović et al. · Annals of the Rheumatic Diseases Open access	17 Oct 2017	124
12	Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study Alan Kivitz, Ulf G. Wagner, Eva Dokoupilová et al. · Rheumatology and Therapy Open access	18 Aug 2018	122
13	Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Michael E. Weinblatt, Asta Baranauskaitė, Eva Dokoupilová et al. · Arthritis & Rheumatology Open access	13 Feb 2018	116
14	One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study Mark C. Genovese, Patrick Durez, Hanno B. Richards et al. · The Journal of Rheumatology Open access	15 Jan 2014	97
15	Association between body height and serve speed in elite tennis players František Vaverka, Miroslav Černošek · Sports Biomechanics	20 Apr 2012	83
16	Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial László Rudolf Hangody, Róbert Sződy, Piotr Łukasik et al. · Cartilage Open access	23 May 2017	82
17	Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study Philip J. Mease, Apinya Lertratanakul, Kim Alexander Papp et al. · Rheumatology and Therapy Open access	28 Apr 2021	79
18	Age is a critical determinant in recovery from multiple sclerosis relapses Brittani L. Conway, Burcu Zeydan, Uğur Uygunoğlu et al. · Multiple Sclerosis Journal	10 Oct 2018	71
19	Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study Sudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński et al. · Annals of the Rheumatic Diseases Open access	22 Mar 2019	61
20	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović et al. · Lara D. Veeken Open access	18 Jul 2017	55
21	FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension Mark C. Genovese, Josephine Glover, Maria Greenwald et al. · Arthritis Research & Therapy Open access	Dec 2019	50
22	Strabismus, refractive errors and nystagmus in children and young adults with Down syndrome Antonela Ljubic, Vladimir Trajkovski, Branislav Stanković · Ophthalmic Genetics	5 Jul 2011	48
23	Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study Karel Pavelká, Alan Kivitz, Eva Dokoupilová et al. · ACR Open Rheumatology Open access	20 Jan 2020	42
24	Efficacy and Safety of Anti–Interleukin‐20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial Ladislav Šenolt, Piotr Leszczyński, Eva Dokoupilová et al. · Arthritis & Rheumatology	23 Feb 2015	42
25	Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis Eva Dokoupilová, Jacob A. Aelion, Tsutomu Takeuchi et al. · Scandinavian Journal of Rheumatology Open access	20 Feb 2018	41
26	Effect of Alloying Elements, Cold Work, and Hydrogen on the Irradiation-Induced Growth Behavior of Zirconium Alloy Variants Suresh K. Yagnik, Ronald B. Adamson, G. P. Kobylyansky et al. Conference paper	2018	35
27	Dual energy CT in patients with acute abdomen; is it possible for virtual non-enhanced images to replace true non-enhanced images? A Lan Im, Young Hwan Lee, Dong Ho Bang et al. · Emergency Radiology	2 Jul 2013	32
28	Stimulation TcPO2 Testing Improves Diagnosis of Peripheral Arterial Disease in Patients With Diabetic Foot Vladimı́ra Fejfarová, Jiří Matuška, Edward Bernard Jude et al. · Frontiers in Endocrinology Open access	10 Dec 2021	29
29	Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve‐week, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study Oliver Distler, Wolfgang Eich, Eva Dokoupilová et al. · Arthritis & Rheumatism Open access	28 Dec 2009	29
30	Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial Frank Behrens, Philipp Sewerin, Eugenio de Miguel et al. · Lara D. Veeken Open access	29 Oct 2021	26
31	OP0258 IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS – 16-WEEK RESULTS FROM A PHASE 2 STUDY Frank Behrens, P. C. Taylor, Dieter Wetzel et al. · Annals of the Rheumatic Diseases Open access	Jun 2022	25
32	Round-Robin Testing of Fracture Toughness Characteristics of Thin-Walled Tubing Suresh K. Yagnik, Natesan Ramasubramanian, Viatcheslav Grigoriev et al. Conference paper	2009	24
33	Análise acústica da voz do idoso: caracterização da freqüência fundamental Erika Mifune, Vanessa da Silva Saraiva Justino, Zuleica Camarg et al. · Revista CEFAC Open access	Jun 2007	23
34	Inulin and Fibersol-2 Combined Have Hypolipidemic Effects on High Cholesterol Diet-Induced Hyperlipidemia in Hamsters Wen-Ching Huang, Che-Li Lin, Yi-Ju Hsu et al. · Molecules Open access	5 Mar 2016	22
35	OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL Mark C. Genovese, Apinya Lertratanakul, Jaclyn K. Anderson et al. · Annals of the Rheumatic Diseases Open access	Jun 2020	21
36	Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study Sławomir Jeka, Eva Dokoupilová, Alan Kivitz et al. · Journal of Bone and Mineral Research Open access	29 Jan 2024	20
37	Emissions with E85 and Gasolines in Flexible/Variable Fuel Vehicles - The Auto/Oil Air Quality Improvement Research Program Jack D. Benson, William J. Koehl, Vaughn R. Burns et al. · SAE technical papers on CD-ROM/SAE technical paper series Conference paper	Oct 1995	20
38	Ophthalmic Manifestations in Children and Young Adults with Down Syndrome and Congenital Heart Defects Antonela Ljubic, Vladimir Trajkovski, Milorad B. Tesic et al. · Ophthalmic Epidemiology	4 Mar 2015	20
39	Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2) Ana‐Maria Orbai, Jordi Gratacós, Anthony M. Turkiewicz et al. · Rheumatology and Therapy Open access	5 Dec 2020	18
40	“What is more important than love?” Parental attachment and romantic relationship in Italian emerging adulthood Alessandra Fermani, Ramona Bongelli, Angelo Carrieri et al. · Cogent Psychology Open access	2019	18
41	Refractive errors in children and young adults with Down’s syndrome Antonela Ljubic, Vladimir Trajkovski · Acta Ophthalmologica	16 Oct 2009	18
42	Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study Thomas Wilke, Burkhard Weisser, Hans‐Georg Predel et al. · DOAJ (DOAJ: Directory of Open Access Journals) Open access	Feb 2022	17
43	Quantitative assessment of the serve speed in tennis František Vaverka, Miroslav Černošek · Sports Biomechanics	2 Jan 2016	16
44	Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study Peter Charles Taylor, Philip J. Mease, Kurt de Vlam et al. · Annals of the Rheumatic Diseases Open access	11 Apr 2025	12
45	Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12 Bente Lomholdt Langdahl, Yoon‐Sok Chung, Rafal Plebanski et al. · The Journal of Clinical Endocrinology & Metabolism Open access	7 Sep 2024	12
46	Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study Alan Kivitz, Xenofon Baraliakos, Elena Tomaselli Muensterman et al. · Annals of the Rheumatic Diseases Open access	3 Jul 2025	11
47	Comparative evaluation of the white matter fiber integrity in patients with prelingual and postlingual deafness Jinna Kim, Jae Young Choi, Jinseok Eo et al. · Neuroreport Open access	7 Sep 2017	10
48	Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe NEMANJA S. DAMJANOV, Sarolta Kárpáti, Lajos V. Kemény et al. · Journal of Dermatological Treatment Open access	16 May 2017	10
49	SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial Yoon‐Sok Chung, Bente Lomholdt Langdahl, Rafal Plebanski et al. · Bone Open access	13 Dec 2024	8
50	Epidemiological survey of tick-borne encephalitis virus and Anaplasma phagocytophilum co-infections in patients from regions of the Czech Republic endemic for tick-borne diseases Petr Zeman, Petr Pazdiora, Václav Chmelı́k et al. · Wiener klinische Wochenschrift	Sep 2007	8

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.